ARA-290 vs Dihexa
Both ARA-290 and Dihexa are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
ARA-290
Evidence BARA-290 (Cibinetide)
An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.
View full ARA-290 profile →Dihexa
Evidence CDihexa (PNB-0408)
An angiotensin IV-derived hexapeptide that mimics hepatocyte growth factor (HGF)/c-Met signaling and produced rapid synaptogenesis in animal models. No human trials.
View full Dihexa profile →Side-by-Side
| Attribute | ARA-290 | Dihexa |
|---|---|---|
| Evidence Grade | B | C |
| FDA Status | Not FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathy | Not FDA-approved — research compound (HGF/c-Met-mimetic) |
| Typical Dose | Trial range: 1–4 mg subcutaneous daily | 8–45 mg orally daily (research-only) |
| Clinics Indexed | 9 | 10 |
| Categories | anti-inflammatory, neuroprotection | cognitive, neuroprotection |
Key reported benefits — ARA-290
- ✓Small-fiber neuropathy improvement
- ✓Anti-inflammatory
- ✓No erythrocytosis
Key reported benefits — Dihexa
- ✓Synaptogenesis (preclinical)
- ✓Memory improvement (animal)
- ✓Possible Alzheimer's relevance
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.